Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un primer estudio en humano de KK2223 en participantes con linfoma no Hodgkin de células T recurrentes o refractarias

29 de septiembre de 2026 actualizado por: Kyowa Kirin, Inc.

Un estudio de fase 1, multicéntrico, abierto, no aleatorizado, escala de dosis y relleno de KK2223 en participantes con linfoma no Hodgkin de células T recurrentes o refractarias

The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Descripción detallada

This is a Phase 1, multicenter, open-label, non randomized study in participants with relapsed or refractory PTCL or CTCL. This study consists of Part 1 (dose-escalation) and Part 2 (backfill). The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of K2223 in r/r T-cell NHL (PTCL or CTCL)

Tipo de estudio

Intervencionista

Inscripción (Estimado)

72

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Madrid, España, 28027
        • Aún no reclutando
        • Clinica Universidad de Navarra - Hematología y Hemoterapia
        • Contacto:
          • Miguel Canales Albendea
          • Número de teléfono: 34917277116
          • Correo electrónico: macanales@unav.es
        • Investigador principal:
          • Migue Canales Albendea
    • Barcelona
      • Badalona, Barcelona, España, 8036
        • Aún no reclutando
        • Hospital Clinic De Barcelona - Hematología
        • Investigador principal:
          • Pablo Mozas
        • Contacto:
          • Pablo Mozas
          • Número de teléfono: 34 93 227 22 71
          • Correo electrónico: mozas@clinic.cat
      • L'Hospitalet de Llobregat, Barcelona, España, 8907
        • Aún no reclutando
        • Institut Català d'Oncologia (ICO) - ICO L'Hospitalet - Hematologia
        • Investigador principal:
          • Eva Domingo Domenech
        • Contacto:
    • Navarre
      • Pamplona, Navarre, España, 31008
        • Aún no reclutando
        • Clinica Universidad de Navarra - Hematología
        • Contacto:
          • Miguel Canales Albendea
          • Número de teléfono: 34917277116
          • Correo electrónico: macanales@unav.es
        • Investigador principal:
          • Miguel Canales Albendea
    • California
      • Duarte, California, Estados Unidos, 91010
        • Aún no reclutando
        • City of Hope
        • Investigador principal:
          • Christina Poh
        • Contacto:
          • Christina Poh
          • Número de teléfono: 916-734-7131
          • Correo electrónico: cpoh@coh.org
      • Orange, California, Estados Unidos, 92868
        • Aún no reclutando
        • University of California, Irvine Medical Center - Hematology/Oncology
        • Contacto:
          • Lauren Pinter Brown
          • Número de teléfono: 7144568200
          • Correo electrónico: lpinterb@uci.edu
        • Investigador principal:
          • Lauren Pinter Brown
      • Stanford, California, Estados Unidos, 94305
        • Reclutamiento
        • Stanford University School of Medicine
        • Investigador principal:
          • Youn Kim
        • Contacto:
    • Florida
      • Tampa, Florida, Estados Unidos, 33612
        • Aún no reclutando
        • Moffit Cancer Center
        • Contacto:
        • Investigador principal:
          • Yumeng Zhang
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Aún no reclutando
        • Emory University Medical Center
        • Investigador principal:
          • Pamela Allen
        • Contacto:
          • Pamela Allen
          • Número de teléfono: 404-778-2407
          • Correo electrónico: pallen5@emory.edu
    • Iowa
      • Iowa City, Iowa, Estados Unidos, 52242
        • Aún no reclutando
        • University of Iowa Health
        • Investigador principal:
          • Eric Mou
        • Contacto:
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • Aún no reclutando
        • Beth Israel Deaconess Medical Center - Research
        • Contacto:
        • Investigador principal:
          • Salvia Jain
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Reclutamiento
        • Washington University School of Medicine - Oncology Hospital - Public
        • Investigador principal:
          • Neha Mehta Shah
        • Contacto:
          • Neha Mehta Shah
          • Número de teléfono: 314.273-8566
          • Correo electrónico: mehta-n@wustl.edu
    • New Jersey
      • Hackensack, New Jersey, Estados Unidos, 07601-2105
        • Aún no reclutando
        • Hackensack University Medical Center - John Theurer Cancer C - Lymphoma Division
        • Investigador principal:
          • Tatyana Feldman
        • Contacto:
    • New York
      • New York, New York, Estados Unidos, 10021-6007
        • Reclutamiento
        • Memorial Sloan Kettering Cancer Center
        • Investigador principal:
          • Jasmine Zain
        • Contacto:
          • Jasmine Zain
          • Número de teléfono: 212-639-3045
          • Correo electrónico: zainj1@mskcc.org
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44106
        • Aún no reclutando
        • University Hospitals Cleveland Medical Center
        • Contacto:
        • Investigador principal:
          • Kevin Cooper
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Aún no reclutando
        • Oregon Health & Science University
        • Contacto:
          • Craig Okada
          • Número de teléfono: 503-494-8397
          • Correo electrónico: okadac@ohsu.edu
        • Investigador principal:
          • Craig Okada
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Aún no reclutando
        • University of Pennsylvania - Abramson Cancer Center
        • Investigador principal:
          • Stefan Barta
        • Contacto:
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • The University of Texas - MD Anderson Cancer Center
        • Investigador principal:
          • Ranjit Nair
        • Contacto:
      • Bergamo, Italia, 24127
        • Aún no reclutando
        • Azienda Ospedaliera Papa Giovanni XXIII - Ematologia
        • Investigador principal:
          • Giuseppe Gritti
        • Contacto:
      • Bologna, Italia, 40138
        • Aún no reclutando
        • Azienda Ospedaliero Universitaria di Bologna IRCCS (Policlinico di Sant'Orsola) - Ematologia
        • Contacto:
        • Investigador principal:
          • Luigi Zinzani Pier
      • Torino, Italia, 10126
        • Aún no reclutando
        • AOU Citta' della Salute e della Scienza di Torino Ospedale Molinette, Ematologia Universitaria
        • Contacto:
          • Federica Cavallo
          • Número de teléfono: 390116334264
          • Correo electrónico: f.cavallo@unito.it
        • Investigador principal:
          • Federica Cavallo
    • Torino
      • Candiolo, Torino, Italia, 10060
        • Aún no reclutando
        • Istituto di Candiolo, IRCCS - Oncologia Medica ed Ematologia
        • Investigador principal:
          • Umberto Vitolo
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including nodal T-follicular helper cell lymphoma, ALCL, PTCL NOS) for Parts 1 and 2; CTCL (mycosis fungoides or Sézary syndrome, stages IIB-IV) for Parts 1 and 2, with specific disease involvement criteria in Part 2.
  • PTCL participants must have relapsed/refractory/intolerant to ≥1 systemic therapy; CD30+ PTCL must have prior brentuximab vedotin treatment or intolerance, and/or ALK-positive ALCL participants should have previously received crizotinib if indicated (crizotinib administration is applicable to US sites only). CTCL participants must have relapsed/refractory/intolerant to ≥2 systemic therapies.
  • Availability of tumor tissue (current or archival) is required.
  • Measurable disease required: nodal/extranodal lesions for PTCL and assessable skin disease for CTCL.
  • ECOG performance status 0-1; adequate neutrophils (≥1000/µL), platelets (≥75,000/µL), renal function (creatinine clearance ≥60 mL/min), liver function within defined limits, and total bilirubin ≤1.5× ULN (up to 3× ULN with Gilbert's syndrome).
  • Body weight 40 kg to ≤ 200 kg
  • Life expectancy ≥3 months.
  • Negative pregnancy test for females of childbearing potential; contraception required for females and males with partners of childbearing potential during and after treatment.
  • Restrictions on gamete donation and freezing during and after treatment.
  • Ability to provide informed consent and comply with study procedures. -

Exclusion Criteria:

  • Recent autologous or allogeneic transplant within 120 days before treatment; active GVHD or ongoing immunosuppression after allogeneic transplant; prior HSCT and with active VOD/SOS
  • Pregnant or breastfeeding females, or those intending pregnancy.
  • History of HIV, HBV, or HCV infections generally excluded, except for controlled or resolved cases as defined.
  • Uncontrolled infections requiring antibiotics, antivirals, or antifungals at screening through treatment start.
  • Significant medical history or complications within six months prior to enrollment, including advanced congestive heart failure (NYHA Class III or higher), recent unstable angina or myocardial infarction, autoimmune diseases requiring systemic immunosuppressive therapy, active or uncontrolled ocular diseases, Grade 3 or 4 peripheral neuropathy, or other poorly controlled conditions as judged by the investigator (e.g., uncontrolled hypertension, diabetes, or arrhythmias).
  • Use of other investigational drugs within 14 days or 5 half-lives before treatment.
  • Steroid use over 10 mg/day prednisone equivalent within 14 days prior, except limited corticosteroid use with specific tapering guidelines; topical steroids allowed under conditions for CTCL.
  • Major surgery, radiotherapy, chemotherapy, or other anti-cancer treatments within 14 days or 5 half-lives before treatment.
  • Prior mogamulizumab use within six months before treatment; associated rash must be ruled out if >6 months.
  • Known history of Grade ≥ 3 hypersensitivity to mogamulizumab.
  • Failure to recover from prior non-hematologic toxicities to Grade 0 or 1 (except alopecia and mild neuropathy).
  • Prolonged QT/QTc interval (e.g., QTcF >480 ms).
  • Active second primary malignancies except specified non-exclusionary cases.
  • CNS involvement.
  • Any condition that may impair compliance or study completion as judged by the Investigator.
  • Known hypersensitivity to any excipients in the drug formulation.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part One (Dose Escalation)

In Part 1, safety and tolerability of KK2223 in relapsed/refractory PTCL or CTCL patients will be assessed using a BOIN dose-escalation design.

Intravenous infusion

Experimental: Part Two (Backfill)

Part 2 will collect additional data, with dose levels and cohort size based on Part 1 results, administering doses approved for tolerability. Backfill cohorts at cleared doses may open, prioritizing Part 1 enrollment.

Intravenous infusion

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 (all 72 potentially treated subjects)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years

Vital signs (mmHg in Systolic/Diastolic blood pressure)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years

Pulse rate (beats/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years

Respiratory Rate (breath/min)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years

Temperature (°Celcius)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years

ECG parameters (PR interval, QRS interval, QT interval, QTc interval)

Through study completion, an average of 1.5 years
Assess the incidence of treatment-emergent adverse events and determine the maximum tolerated dose (MTD) of KK2223 in patients with relapsed or refractory peripheral or cutaneous T cell lymphoma (PTCL/CTCL).
Periodo de tiempo: Through study completion, an average of 1.5 years

Number of participants with dose-limiting toxicities (DLTs) in Part 1 only (at most 27 participants) and assess maximum tolerated dose (MTD)

Through study completion, an average of 1.5 years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Mean Blood Drug Concentration
Periodo de tiempo: Through study completion, an average of 1.5 years

The mean drug concentration in the blood

Through study completion, an average of 1.5 years
To evaluate the immunogenicity of KK2223.
Periodo de tiempo: Through study completion, an average of 1.5 years

Incidence of Anti drug antibodies (ADA) in blood

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years

% in Overall Response Rate (ORR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years

% in Compartment Response (if applicable)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years

Time unit (week/month) in Duration of Response (DOR)

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Next Treatment (TTNT) will be evaluated

Through study completion, an average of 1.5 years
To evaluate the preliminary anti-tumor activity of KK2223 (Investigator assessed).
Periodo de tiempo: Through study completion, an average of 1.5 years

Time unit (week/month) in Time To Response (TTR)

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Maximum Blood Concentration (Cmax)
Periodo de tiempo: Through study completion, an average of 1.5 years

The maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUC)
Periodo de tiempo: Through study completion, an average of 1.5 years

A measure of the overall drug exposure over time

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Time to Maximum Concentration (Tmax)
Periodo de tiempo: Through study completion, an average of 1.5 years

The time taken to reach the maximum drug concentration

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Terminal Half-Life (Thalf)
Periodo de tiempo: Through study completion, an average of 1.5 years

The time required for the drug concentration to decrease by 50%

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Clearance (CL)
Periodo de tiempo: Through study completion, an average of 1.5 years

Rate of drug elimination from the body

Through study completion, an average of 1.5 years
Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss)
Periodo de tiempo: Through study completion, an average of 1.5 years

Theoretical volume of distribution at steady state and reflects the extent of drug istribution into tissues

Through study completion, an average of 1.5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de septiembre de 2026

Finalización primaria (Estimado)

1 de marzo de 2029

Finalización del estudio (Estimado)

1 de septiembre de 2030

Fechas de registro del estudio

Enviado por primera vez

12 de agosto de 2025

Primero enviado que cumplió con los criterios de control de calidad

17 de septiembre de 2025

Publicado por primera vez (Actual)

25 de septiembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

30 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

29 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2223-001

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .